Plunkett Research Online: argenx

ARGENX (ARGX:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

argenx SE is a clinical stage biotechnology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Its product pipeline includes product candidates such as ARGX-113, ARGX-110, ARGX-115, AR.....



argenx
Ticker: ARGX
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 31 763030488
Fax:
Address: Willemstraat 5
Breda, 4811 Netherlands

Types Of Business
Industry Ranks

Industry NAICS code:


Ranks not available
ContactsDescription
Tim HauwermeirenCEO/Director
Eric CastaldiCFO
See More
argenx SE is a clinical stage biotechnology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Its product pipeline includes product candidates such as ARGX-113, ARGX-110, ARGX-115, AR.....See More See More

Auditor: Deloitte Accountants B.V.
Legal Advisor:
$USD, In whole numbers,
except marked * or %
201720162015201420132012
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
NameTitleSalary (EUR)Bonus (EUR)
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: